Your browser is no longer supported. Please, upgrade your browser.
Settings
JSPR [NASD]
Jasper Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own25.70% Shs Outstand12.50M Perf Week106.28%
Market Cap626.75M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month64.04%
Income-4.30M PEG- EPS next Q- Inst Own57.10% Short Float- Perf Quarter65.52%
Sales- P/S- EPS this Y-986.70% Inst Trans120.08% Short Ratio0.06 Perf Half Y65.86%
Book/sh6.90 P/B2.38 EPS next Y- ROA-4.30% Target Price- Perf Year65.03%
Cash/sh0.01 P/C2089.17 EPS next 5Y- ROE-4.80% 52W Range7.11 - 18.24 Perf YTD64.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.98% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low130.94% ATR2.59
Employees24 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)66.18 Volatility38.41% 26.96%
OptionableNo Debt/Eq0.00 EPS Q/Q-4.00% Profit Margin- Rel Volume17.42 Prev Close12.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.05M Price16.42
Recom- SMA2058.09% SMA5062.10% SMA20063.15% Volume35,656,400 Change31.57%
Oct-13-21Initiated Oppenheimer Outperform $21
Oct-15-21 09:39PM  
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.